Member Log-in

I forgot my password

Not a Member? Register

Resources

Our resource library is a searchable collection of tools and documents related to various technical areas around the Gavi transition. The library consists of research articles, policy briefs, reports, guidebooks, country data, and other resources pertinent to Gavi transition or immunization programs generally. You can filter the resources by topic, type, or country. Some resources are available to LNCT members only and will require logging in to view.

Resources

Results 1 -10 of 20

Assessing the Incremental Costs and Savings of Introducing Electronic Immunization Registries and Stock Management Systems: Evidence from the Better Immunization Data Initiative in Tanzania and Zambia

Introduction: poor data quality and use have been identified as key challenges that negatively impact immunization programs in low- and middle-income countries (LMICs). In addition, many LMICs have a shortage of health personnel, and staff available have demanding workloads across several health programs. In order to address these challenges, the Better Immunization Data (BID) Initiative introduced a comprehensive suite of interventions,

Continued

Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30

ABSTRACT

Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. We estimated economic benefits using cost-of-illness and value-of-a-statistical-life approaches and combined this estimation with immunization program costs to derive the return on investment from immunization programs against ten pathogens for ninety-four low- and middle-income countries for the period 2011–30.

Continued

Immunization Delivery Cost Catalogue (IDCC)

The Immunization Delivery Cost Catalogue (IDCC) is the most comprehensive, current, and standardized global evidence on the cost of delivering vaccines. In January 2017 and again in April 2018 and December 2019, ThinkWell completed a systematic review of the current evidence base on immunization delivery costs (IDC)*. The IDCC was built to answer a question frequently asked by national and global immunization stakeholders: “What are the unit costs of vaccine delivery across different LMICs and through a variety of delivery strategies?”

Continued

Teaching Vaccine Economics Everywhere (TVEE) Course Materials

1.     Health Economics for Vaccines

The process of creating vaccines, manufacturing, distributing, and injecting them into individuals is a complex process requiring multiple decisions by multiple groups and individuals. On the supply side there are pharmaceutical companies, regulatory authorities, distributors, and thousands of health care workers who have to make strategic choices.

Continued

ProVac Toolkit: Providing Tools to Support Vaccine Decision Making at Country-level

PAHO’s ProVac Initiative helps national immunization programs managers and policymakers make more robust, evidence based decisions. Since 2004, the ProVac Initiative and its collaborators have trained hundreds of people at ministries of health in the Americas and elsewhere on the development and use of vaccine impact, cost and cost-effectiveness data to inform decision making. More than 30 countries have received direct technical assistance to conduct cost or cost-effectiveness analyses on immunization programs from the Initiative.

Continued

Papillomavirus Rapid Interface for Modelling and Economics (PRIME) Tool

The spreadsheet-based PRIME tool is intended for in-country analysts (not necessarily economists) who are advising national governments on HPV vaccine introduction.

PRIME is designed to give users an idea of:

    • The magnitude of the burden of cervical cancer
    • The impact of introducing HPV vaccination for girls prior to sexual debut
    • Healthcare costs incurred as a result of cervical cancer treatment
    • Costs associated with vaccination
    • Long-term savings which may result from a vaccination program

The tool is intended for use by non-modeller users such as country program managers and planners and decision makers in low- and middle income countries.

Continued

Re-evaluating the Potential Impact and Cost-effectiveness of Rotavirus Vaccination in 73 Gavi Countries: A Modelling Study

Background Previous studies have found rotavirus vaccination to be highly cost-effective in low-income countries. However, updated evidence is now available for several inputs (ie, rotavirus disease mortality rates, rotavirus age distributions, vaccine timeliness, and vaccine efficacy by duration of follow-up), new rotavirus vaccines have entered the market, vaccine prices have decreased, and cost-effectiveness thresholds have been re-examined. We aimed to provide updated cost-effectiveness estimates to inform national decisions about the new introduction and current use of rotavirus vaccines in Gavi countries. … Continued

WHO Guide for Standardization of Economic Evaluations of Immunization Programs

WHO has recently published a new edition of the guidance to meet the increased need to carry out immunization economic evaluations for decision making using the latest methodologies.

This updated guide brings together the recommendations and guidance from many recent guidelines, tools and other documents on specific aspects of immunization and on specific vaccines.

Continued

The Costs of Delivering Vaccines in Low- and Middle-income Countries: Findings from a Systematic Review

Abstract
Information on immunization delivery costs (IDCs) is essential for better planning and budgeting for the sustainability and performance of national programs. However, delivery cost evidence is fragmented and of variable quality, making it difficult for policymakers, planners, and other stakeholders to understand and use. This study aimed to consolidate and summarize the evidence on delivery costs,

Continued

Sustaining Pneumococcal Vaccination After Transitioning from Gavi Support: A Modelling and Cost-effectiveness Study in Kenya

Background
In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to reach the threshold at which countries transition from Gavi support to self-financing (3-year average gross national income per capita of US$1580), they will need to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or to discontinue PCV in their childhood immunisation programmes.

Continued

Choose a Language